🔗 Visit the ClinicalTrials.gov page for NCT00993499
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. | Clin Cancer Res | 2014 | 1.33 |
| 2 | Molecular pathways and therapeutic targets in lung cancer. | Oncotarget | 2014 | 1.16 |
| 3 | Novel agents and strategies for overcoming EGFR TKIs resistance. | Exp Hematol Oncol | 2014 | 1.01 |
| 4 | Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response. | Cancer Res | 2012 | 0.95 |
| 5 | Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. | Onco Targets Ther | 2013 | 0.85 |
| 6 | Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials. | Curr Oncol | 2012 | 0.81 |
| 7 | The pharmacogenomics of drug resistance to protein kinase inhibitors. | Drug Resist Updat | 2016 | 0.75 |